SCHEMBL5570675

SCHEMBL5570675

CC(C)(C)c1ccc(/C=C/C=C/C(=O)N2CCN(CCCCCCCCN3CCN(C(=O)/C=C/C=C/c4ccc(C(C)(C)C)cc4)CC3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 5/20 0.56
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
HPGD P15428 2/20 0.54
GAA P10253 3/20 0.53
LMNA P02545 2/20 0.53
CYP1A2 P05177 1/20 0.47
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTT P42858 1/20 0.46
DRD2 P14416 1/20 0.44
DRD3 P35462 1/20 0.44
HRH2 P25021 1/20 0.44
HRH1 P35367 1/20 0.44
ALOX5 P09917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5569629 1.00 GPR183 (0.56) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
Hydrochloric Acid SCHEMBL5570669 0.99 GPR183 (0.55) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
Hydrochloric Acid SCHEMBL5570664 0.99 GPR183 (0.55) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL6785345 0.85 ALDH1A1 (0.72) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL5572606 0.84 GPR183 (0.52) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL5572610 0.84 GPR183 (0.52) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
Hydrochloric Acid SCHEMBL5573111 0.83 GPR183 (0.51) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
Hydrochloric Acid SCHEMBL5573117 0.83 GPR183 (0.51) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL4375408 0.81 ALDH1A1 (0.67) GPR183ALDH1A1SMN1; SMN2MAPTNPC1
SCHEMBL14190910 0.81 ALDH1A1 (0.67) GPR183ALDH1A1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 GPR183 1967/4885ALDH1A1 2028/4885SMN1; SMN2 4567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.